Results 231 to 240 of about 303,574 (253)

Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer

Lung Cancer, 2013
Yi-Long Wu, Chongrui Xu, Zhen Wang
exaly  

Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR -mutant glioblastoma

CNS Oncology, 2019
Igor Makhlin, Fadi Jacob, Arati Desai
exaly  

Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma

Expert Opinion on Investigational Drugs, 2008

exaly  

Tyrosine Kinase Inhibitor-Induced Hypertension: Role of Hypertension as a Biomarker in Cancer Treatment

Current Vascular Pharmacology, 2019
Daniela Grimm, Markus Wehland, Nils Erik Magnússon   +2 more
exaly  

Inhibitors of brutons tyrosine kinase

2012
HONIGBERG LEE, VERNER ERIK, PAN ZHENGYING, MODY TARAK   +3 more
openaire   +10 more sources

INHIBITORS OF TYROSINE KINASES

2004
BREITENSTEIN WERNER, FURET PASCAL, JACOB SANDRA, MANLEY PAUL W   +3 more
openaire   +11 more sources

Tyrosine kinase inhibitors

2007
LIM JONGWON, ORTEGA GABARDA ANA ESTHER
openaire   +2 more sources

Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor

Cancer Chemotherapy and Pharmacology, 2010
Mrinal Gounder, Robert G Maki Md Phd Facp Fasco, Maki Robert G   +2 more
exaly  

Rociletinib, a third generation EGFR tyrosine kinase inhibitor: current data and future directions

Expert Opinion on Pharmacotherapy, 2016
Ameen A Salahudeen, Heather Wakelee
exaly  

Tyrosine kinase inhibitors

2018
HOLLAND SACHA, SINGH RAJINDER, BHAMIDIPATI SOMASEKHAR, DING PINGYU, KOLLURI RAO, DARWISH IHAB, MASUDA ESTEBAN, YU JIAXIN   +7 more
openaire   +5 more sources